Literature DB >> 25396308

A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria.

Marcelo F Benveniste1, Robert J Korst, Arun Rajan, Frank C Detterbeck, Edith M Marom.   

Abstract

Measuring tumor response to chemotherapy is important for both clinical decision-making and for multi-institutional studies. Thymoma tends to spread along the pleura: a challenge for accurate tumor measurement. Inaccurate and inconsistent tumor measurements often compromise results from clinical trials that are dependent on identifying response rate and progression-free survival. In this article, we sought to provide a practical guide on how to measure thymoma by the International Thymic Malignancy Interest Group's recommendations for standard outcome measures. The aim of this article is to clarify this measuring technique, lead to consistency between institutions, and minimize intra- and interobserver variability.

Entities:  

Mesh:

Year:  2014        PMID: 25396308     DOI: 10.1097/JTO.0000000000000296

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  16 in total

1.  Outcome of nonsurgical treatment for locally advanced thymic tumors.

Authors:  Chang-Lu Wang; Lan-Ting Gao; Chang-Xing Lv; Lei Zhu; Wen-Tao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

Review 2.  Precision medicine in myasthenia graves: begin from the data precision.

Authors:  Hai-Feng Li; Yu Hong; Yanchen Xie; Hong-Jun Hao; Ren-Cheng Sun
Journal:  Ann Transl Med       Date:  2016-03

Review 3.  Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Authors:  Suchit H Patel; Andreas Rimner; Roger B Cohen
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 4.  PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Authors:  Matthew F Covington; Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

5.  Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.

Authors:  Yusuke Okuma; Yukio Hosomi; Kageaki Watanabe; Satoshi Takahashi; Tatsuru Okamura; Tsunekazu Hishima
Journal:  Int J Clin Oncol       Date:  2015-12-08       Impact factor: 3.402

6.  Simultaneous thoracoscopic resection for coexisting pulmonary and thymic lesions.

Authors:  Feng Lin; Zhilan Xiao; Jiandong Mei; Chengwu Liu; Qiang Pu; Lin Ma; Hu Liao; Chenglin Guo; Yunke Zhu; Yongsheng Zhao; Chuan Li; Jian Li; Lunxu Liu
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

7.  Simultaneous resection of thymic and bronchial carcinoid tumors in a patient diagnosed with multiple endocrine neoplasia type 1.

Authors:  Ulaş Kumbasar; Süleyman Nahit Şendur; Yiğit Yılmaz; Tomris Erbaş; Sevgen Önder; Rıza Doğan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-06-21       Impact factor: 0.332

Review 8.  The expanding role of radiation therapy for thymic malignancies.

Authors:  Jonas Willmann; Andreas Rimner
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

9.  S-1 salvage chemotherapy for stage IV thymic carcinoma: a study of 44 cases.

Authors:  Chang-Lu Wang; Lan-Ting Gao; Chang-Xing Lu
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

10.  Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Authors:  Lukas Kirzinger; Sandra Boy; Jörg Marienhagen; Gerhard Schuierer; Reiner Neu; Michael Ried; Hans-Stefan Hofmann; Karsten Wiebe; Philipp Ströbel; Christoph May; Julia Kleylein-Sohn; Claudia Baierlein; Ulrich Bogdahn; Alexander Marx; Berthold Schalke
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.